Transapical mitral valve repair with LifeClip system: Early outcome of a single center
- VernacularTitle:经心尖二尖瓣夹合术单中心早期临床结果
- Author:
Hang YANG
1
;
Huiping ZHENG
1
;
Haibo FENG
1
;
Hong ZHAO
1
;
Yunpeng LING
1
Author Information
1. Department of Cardiac Surgery, Peking University Third Hospital, Beijing, 100191, P. R. China
- Publication Type:Journal Article
- Keywords:
Mitral regurgitation;
transapical mitral valve repair;
LifeClip system
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(05):572-576
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of transapical mitral valve repair with moderate-to-severe or severe mitral regurgitation (MR) by using LifeClip system. Methods We retrospectively analyzed the clinical data of 7 symptomatic patients with moderate-to-severe or severe MR who received transapical mitral valve repair by using the LifeClip system in our hospital from July to November 2021. There were 5 males and 2 females with an average age of 76.0±7.5 years. Results There were 2 patients with degenerative MR and 5 patients with functional MR. All of the procedures were successful and 6 patients received 1 LifeClip while the other one patient received 2. The operation time was 135.7±46.9 min, the mechanical ventilation time was 12 (3, 14) h, and the hospital stay time was 18.1±4.1 d. No serious complications or death occurred during the perioperative or follow-up period. MR reduction by ≥ grades was achieved in all the patients at the one-month follow-up. The classification of cardiac function was improved in varying degrees. Conclusion Transapical mitral valve repair using the LifeClip system shows good safety and efficacy for severe MR patients, and MR degree is significantly improved at early follow-up. However, the benefit of LifeClip should be validated in a larger sample size of Chinese population and through long-term follow-up.
